Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879176 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL3348926 | 0.84 | S1PR4 (0.48) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL18876413 | 0.84 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL13140527 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL22945653 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL13801136 | 0.81 | KDM4E (0.44) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL21790195 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL9048215 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL18879678 | 0.80 | KDM4E (0.46) | ALDH1A1KDM4EHPGDMAPTTDP1 | |
| SCHEMBL10287183 | 0.80 | KDM4E (0.58) | ALDH1A1KDM4EHPGDMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358871-B2 | Photochemical synthesis of vitamin D3 using sensitizers | FERMENTA BIOTECH LIMITED (IN) | 2025-07-15 | — | — | US | claimed |
| US-20220372065-A1 | SYNTHESIS OF CHOLESTEROL AND VITAMIN D3 FROM PHYTOSTEROLS | FERMENTA BIOTECH LIMITED (IN) | 2022-11-24 | — | — | US | claimed |
| US-20220298106-A1 | IMPROVED PHOTOCHEMICAL SYNTHESIS OF VITAMIN D3 USING SENSITIZERS | FERMENTA BIOTECH LIMITED (IN) | 2022-09-22 | — | — | US | claimed |
| US-20220372065-A1 | SYNTHESIS OF CHOLESTEROL AND VITAMIN D3 FROM PHYTOSTEROLS | FERMENTA BIOTECH LIMITED (IN) | 2022-11-24 | — | — | US | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| EP-1357912-B1 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20120041356-A1 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE | QLT INC. (CA) | 2012-02-16 | — | — | US | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035997-A2 | USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| US-6184540-B1 | SEMICONDUCTOR HAVING A LAYER OF A POLYTHIOPHENE DERIVED FROM A SOLUBLE PRECURSOR COMPOUND OF TETRAHYDROTHIOPHENE OR TETRAHYDROFURAN UNITS HAVING THERMALLY SEPARABLE ARYL- OR ALKYL-THIO SUBSTITUENTS, WHICH CAN BE PROCESSED FROM SOLUTION | U.S. PHILIPS CORPORATION | 2001-02-06 | — | — | US | disclosed |
| US-6124475-A | Method of preparing a thiophene-containing or furan-containing conjugated compound and precursor compound used therein | U.S. PHILIPS CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
| US-5919951-A | Method of preparing a thiophene-containing or furan-containing conjugated compound and precursor compound used therein | U.S. PHILIPS CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0867437-A1 | \"Method of preparing a thiophene-containing or furan -containing conjugated compound and precursor compound used therein\". | Koninklijke Philips Electronics N.V. (NL) | 1998-09-30 | — | — | EP | disclosed |
| EP-0454204-B1 | Method for the photochemical isomeration of organic compounds under the influence of a photosensitizer | DUPHAR INT RES (NL) | 1995-06-28 | — | — | EP | disclosed |
| US-5252191-A | Method for the photochemical isomerization of organic compounds under the influence of a photosensitizer | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1993-10-12 | — | — | US | disclosed |
| EP-0454204-A2 | Method for the photochemical isomeration of organic compounds under the influence of a photosensitizer | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372065-A1 | SYNTHESIS OF CHOLESTEROL AND VITAMIN D3 FROM PHYTOSTEROLS | CYP2R1, CYP46A1, CYP24A1 | ALDH1A1 2914/4885KDM4E 1043/4885HPGD 181/4885 |
| US-12358871-B2 | Photochemical synthesis of vitamin D3 using sensitizers | CYP2R1, CYP24A1, VDR | ALDH1A1 651/4885KDM4E 3208/4885HPGD 122/4885 |
| US-20220298106-A1 | IMPROVED PHOTOCHEMICAL SYNTHESIS OF VITAMIN D3 USING SENSITIZERS | CYP2R1, CYP24A1, CYP27B1 | ALDH1A1 777/4885KDM4E 3253/4885HPGD 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.